Loading
A phase 2 trial of carboplatin, paclitaxel / nab-paclitaxel, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting.
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06318897 by M.D. Anderson Cancer Center, with a registry enrolment figure of 28 participants, started 2024-05-29 and due to reach its primary completion in 2027-09-30. Interventions recorded: Carboplatin; Paclitaxel; Pembrolizumab; Doxorubicin; Cyclophosphamide. Conditions listed: Stage 1 cT1b-T1cN0M0; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants must have histologically confirmed ER negative, PR negative and HER2-negative (TNBC) defined as ER\<10%, PR\<10%, and HER2 negative (per 2018 ASCO CAP guidelines)". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.